Form 4: Phathom Pharmaceuticals Grants Chief Legal Officer 210,000 Stock Options

Anne Marie Cook, Chief Legal Officer and Corporate Secretary of Phathom Pharmaceuticals, Inc., was granted 210,000 stock options with an exercise price of $9.47, vesting over four years.

Summary

• Anne Marie Cook, the Chief Legal Officer and Corporate Secretary of Phathom Pharmaceuticals, Inc. (PHAT), was granted 210,000 stock options.
• The transaction date for this grant was June 23, 2025.
• Each stock option has an exercise price of $9.47.
• The options will vest over a four-year period, with 25% vesting on June 23, 2026, and the remaining shares vesting in equal monthly installments over the subsequent three years.
• Vesting is contingent upon Ms. Cook's continuous service to the Issuer.
• The expiration date for these stock options is June 22, 2035.
• Following this transaction, Anne Marie Cook beneficially owns 210,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is a routine compensation event, generally viewed as a positive for aligning management incentives with shareholder interests, without indicating any immediate negative implications for the company.

Positives

• The grant of stock options aligns the interests of the Chief Legal Officer with those of the shareholders, incentivizing long-term performance and value creation.
• This is a standard form of executive compensation, indicating ongoing commitment to key management personnel.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

The grant of stock options to key executives is a common and widely accepted practice in the pharmaceutical and biotechnology industries, used to attract, retain, and incentivize top talent by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The structure of this stock option grant, including the vesting schedule over several years, is consistent with typical executive compensation packages observed across the pharmaceutical and broader corporate sectors. This aligns with standard practices designed to encourage long-term commitment and performance from executives.

Management Changes

Related Party Transactions

• The grant of stock options to Anne Marie Cook, an officer of Phathom Pharmaceuticals, Inc., constitutes a related party transaction as it involves a transaction between the company and a key management personnel.

Stakeholder Impact

• Shareholders: The grant of options aims to align the executive's financial interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: This transaction is specific to a senior executive and does not directly impact the broader employee base, though it reflects the company's compensation philosophy for leadership.
• Executive (Anne Marie Cook): Directly benefits from the potential future value of the stock options, providing a significant incentive tied to the company's stock performance.

Next Steps

• The stock options will begin vesting on June 23, 2026, with subsequent monthly vesting over the following three years.
• The Chief Legal Officer may choose to exercise these options at any time after they vest and before their expiration date of June 22, 2035, subject to company policy and market conditions.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Stock Option, Executive Compensation, SEC Form 4, Derivative Securities, Vesting, Insider Transaction, Anne Marie Cook